The human genome includes some 30,000 genes. These genes are responsible for coding of functional and structural proteins. A very small number are pharmacogenomics proteins—drug receptors, drug targets, drug metabolizing enzymes and drug transporters—important to accurate and effective medication therapy.
By testing and considering an individual’s genetics relative to the performance of drug metabolizing enzymes, targets, receptors and transporters, healthcare providers can now more precisely help patients to reach optimal drug therapy.
Along with Coriell Life Sciences, a global leader in bioinformatics, we have developed proprietary tools to help identify and assess the potential benefit to individual candidates, as well as applying to large groups to determine the potential impact of a population-wide program, including return on investment. Employers and benefit providers can see the projected impact a testing program would have on the overall health and medical expenses for their population. Following testing, results will be stored to apply to future prescribing.
RxGenomix works directly with pharmacists and other healthcare providers to implement PGx testing across larger populations and for individuals identified at the point of care. We help them initiate the test itself, process the sample and have a full report returned by a CLIA-certified laboratory. The logistics are often a barrier to entry for most physicians and pharmacists, but RxGenomix is there to lead every step of the process.
The full lab report is best interpreted by a pharmacist who has completed the RxGenomix Training Program in Pharmacogenomics. They will review the results, apply our clinical decision support tool and add their clinical judgement to create a concise recommendation to share with the ordering provider. By working together to create a personalized prescribing plan, the pharmacist and prescriber can combine their expertise to put the patient on the optimal path to better health.